Stents, Bioresorbable

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a higher quality of life than a best-in-class, permanent,...

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE...

bioresorbable stents, dissolving stents

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents will eventually replace conventional metallic stents...

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China ac...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is...
Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II, a clinical trial to assess safety and...
A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting...
September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting...
Micell Technologies Inc.'s thin-strut stent features elimination of the coating from the stent in 45-60 days and the complete absorption of

Articles

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is...
ABSORB II Study DES Xience Abbot Vascular
Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and...
bioresorbable stents, dissolving stents, Absorb stent, BVS
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC)...
Elixir Medical Corp. DESolve 100 CE mark
Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

Video Center

By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
3 weeks 3 days ago
As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
6 weeks 5 days ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
12 weeks 3 days ago
This webinar will discuss why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...

Comparison Charts

Sorry there is no data available